AUGUST 11, 2014


Primary Results of the RTOG 0234 Study Published in JCO
Results of RTOG 0234 clinical trial examining concurrent chemoradiotherapy and cetuximab in the postoperative treatment of patients with squamous cell carcinoma of the head and neck (SCCHN) with high-risk pathologic features were published online before print in the Journal of Clinical Oncology on July 7, 2014. The results demonstrate the delivery of postoperative chemoradiotherapy and cetuximab is feasible and tolerable for patients with SCCHN. Furthermore, at 4.4 years median follow up, patients randomized to the docetaxel arm showed more favorable outcome compared with patients in the cisplatin arm. Both arms demonstrated improved disease free survival compared with historical controls. Link to Abstract

New Publications and Abstracts Report Now Available 
You may now view the NRG Publications and Abstracts Report on the NRG Oncology website. Read More

NRG Oncology Introduces Weekly Broadcast
NRG Oncology is pleased to introduce the Weekly Broadcast, a new e-mail communication that provides comprehensive information about NRG Oncology and its clinical trials. Starting today, NRG Oncology will distribute a broadcast each Monday with important information from the operations and Statistics and Data Management Center offices that will include regulatory and protocol updates, membership information, a recent publications’ listing, and other news.

In addition, NRG Oncology will send a monthly newsletter with information about new programs, upcoming group meetings, profiles of investigators, highlights of our science to be presented at major scientific meetings and more news of interest to our research community. Be sure you are on the News Distribution List! Read more

Biologics Holiday Closure

In observance of Labor Day, Biologics, Inc. will be closed Monday, September 1. They will resume regular business hours on Tuesday, September 2. Their regular business hours are Monday through Friday 9am – 6pm ET. If you have questions, please contact the Clinical Research Services team at 800.693.4906, or via email at clinicaltrials@biologicsinc.com

Amendments and Updates
Cancer Prevention & Control
RTOG 1203, Amendment 3: 8/4/2014

Other Protocol Notices
Breast
NSABP B-43
The Rush University Medical Center (RUMC) Department of Pathology updated College of American Pathologists (CAP) accreditation certificate for RUMC has been posted to the B-43 pages on the and
CTSU. websites. This certificate should be kept with local B-43 regulatory documents.

NSABP B-55/BIG 6-13
The Myriad Genetic Laboratories, Inc. Clinical Laboratory Improvement Amendments (CLIA) Certificate of Accreditation has been posted to the CTSU website. This certificate should be kept with local B-55 regulatory documents.

GYN
ANZGOG 0902/GOG-0274/RTOG 1174 OUTBACK Trial
The NHMRC Clinical Trials Center will be conducting major upgrades of its network infrastructure from Friday, August 12th through Sunday, August 15, 2014. This will impact registrations/randomizations. Please plan accordingly. This memo can be found on both the GOG and RTOG (RTOG 1174) legacy websites.

Drug Safety Reports
Safety updates have been issued for GOG legacy studies.

Updated Investigational Brochure
An updated investigation brochure has been issued for RTOG 1122